| Name | Title | Contact Details |
|---|
Starkey Hearing Technologies is much more than the hearing aids we produce. We are in the business of connecting people and changing lives. We believe being able to hear the world and the people around us is as essential to the human experience as breathing. As a world leader in manufacturing and delivering advanced hearing solutions, our goal is to bring people together and make lives richer by empowering individuals to reach their full potential in life. In 1967, William F. Austin founded our company with the simple premise, "Alone we can`t do much. Together, we can change the world." We live that vision every day – and it`s why with every Starkey Hearing Technologies` product purchased, we donate to the Starkey Hearing Foundation to help more people in need around the world receive the gift of hearing. To date we have given over 1 million hearing aids to people around the world.
Daughters of Charity Health System is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Los Altos Hills, CA. To find more information about Daughters of Charity Health System, please visit www.dochs.org
Insight Imaging is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.
Southern Scripts provides innovative and transformative pharmacy benefit management (PBM) solutions that guarantee employers complete flexibility and control over their benefit plan.